Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant interferon alfa · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| recombinant interferon alfa | BIOLOGICAL | - |
| cytarabine | DRUG | - |
| imatinib mesylate | DRUG | - |
DISEASE CHARACTERISTICS: Cytogenetically proven Philadelphia chromosome positive chronic phase chronic myelogenous leukemia (CML) Initial diagnosis within the past 6 months No prior chemotherapy, including regimens used in peripheral blood progenitor cell (PBPC) mobilization for PBPC transplantation...
Top 20 of 60 competitors
Recombinant interferon alfa is an investigational biologic therapy being studied in oncology, specifically for leukemia. It is a protein-based agent developed by Novartis AG under the ticker NVS. The compound is currently in Phase 3 clinical development and has been evaluated in a completed Phase 3 trial in patients with newly diagnosed chronic myelogenous leukemia.
Recombinant interferon alfa has been studied as a treatment for leukemia, specifically in patients with newly diagnosed chronic myelogenous leukemia. It was evaluated in a Phase 3 trial comparing it, in combination with cytarabine, against STI571. The trial has been completed, and the drug remains in Phase 3 development for this oncology indication.
Recombinant interferon alfa is an exogenous protein whose molecular target is F9. It belongs to the exogenous protein target class. This distinguishes it from small-molecule kinase inhibitors, as it is a biologic agent designed to interact with the F9 target as part of its therapeutic mechanism in leukemia.
Recombinant interferon alfa is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor associated with the clinical development of this agent in oncology, specifically for leukemia. The company has advanced the compound into Phase 3 testing.
Recombinant interferon alfa is in Phase 3 clinical development. It is an investigational agent and has not been approved by the FDA. One Phase 3 trial has been completed, and there are currently no active trials listed for this drug. It remains under study for leukemia.
Recombinant interferon alfa has been evaluated in the completed Phase 3 trial NCT00006343, titled STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia. The trial enrolled patients aged 18 years and older in the United States and was an uncontrolled study without randomization or double-blinding.